Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Subjects will receive infusions of PROCHYMAL on Day 42, Day 84, and Day 126 after initial
infusion of PROCHYMAL in Protocol 603. Each infusion will contain 200 million cells. As
subjects will be required to be in Protocol 603 during the entire duration of their
participation in Protocol 611, all concomitant medication and safety information will be
monitored by Protocol 603 and the combination of data from the two protocols

Inclusion Criteria:

- Subject must have qualified for, enrolled in, and provided written ICF and
authorization for use and disclosure of PHI for Protocol 603 after the August 3, 2010.

- Subject successfully completed all screening assessments in Protocol 603 as required
by Protocol 603.

- Subject successfully completed the full course of each of the four infusions of
investigational agent on Days 0, 3, 7, and 14 of Protocol 603 after August 3, 2010.

- Subject must enroll in Protocol 611 on or before the 45th day after first infusion in
Protocol 603.

- Subject must provide written ICF and authorization for use and disclosure of PHI for
Protocol 611.

Exclusion Criteria:

- Subject is unwilling or unable to adhere to requirements of Protocol 611.

- Subject had confirmed respiratory distress during a PROCHYMAL infusion in any prior
PROCHYMAL study.

- Subject had a serious adverse event in any previous PROCHYMAL study that was deemed by
the principal investigator of that study to be possibly or probably related to
PROCHYMAL and also that was within 48 h after a PROCHYMAL infusion.